Start Codon

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatment approaches. This enables patients to access effective and safe treatments for neurological, inflammatory, and oncological conditions.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

NK:IO is a biotechnology company focused on developing natural killer cell-mediated immunotherapies for cancer. The company develops both cell therapies and small molecule therapeutics designed to target cancer and enhance the tumor-killing activity of natural killer cells.

Coding.bio provides AI for cell therapies through automation and computation. They work at the intersection of computation, synthetic biology, and cell therapy. They also provide curative therapeutics for patients.

Enhanc3D Genomics is a functional genomics company focused on the three-dimensional organization of DNA in health and disease. Its GenLink3D platform analyzes how genetic mutations impact distant genes, revealing their influence on disease progression, and it supports large-scale analysis of genetic variation and gene function through high-resolution profiling of 3D genome folding for all genes and their enhancers, enabling researchers to advance novel drugs for areas of unmet medical need.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Semarion is a Cambridge-based company that combines microchip industry materials engineering with cell biology. It aims to revolutionize drug discovery by developing a platform that uses ultra-miniaturized, magnetically steerable wells for adherent cell screening.